YAP1 and non-small cell lung carcinoma: Finally, YAP intensity was reported to be associated with objective responses (partial or complete) of early-stage NSCLC patients treated with preoperative chemotherapy in the IFCT-0002 trial (Table 1): Overall, 63 of the 356 (17.7%) patients studied in this trial showed no response and did not express or expressed low (0–1 intensities) tumoral YAP levels (37.6% [63/134] of patients with low YAP intensity tumor), while 135 patients showed no response and a strongly expressed YAP tumor intensity (60.81% [135/222] of patients with strong tumoral intensity of YAP) (chi2 p-value = 0.011).